Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study
Andrea Picchianti Diamanti(Sapienza University of Rome), Annamaria Iagnocco(University of Turin), Gian Domenico Sebastiani(Carlo Forlanini Hospital), Maria Sole Chimenti(University of Rome Tor Vergata), Marco Canzoni(Azienda Sanitaria Locale Viterbo), Ivan Giovannini(University of Udine), Paolo Falsetti(University of Siena), Donatella Fiore(University of Salerno), Valentino Paci(Marche Polytechnic University), Chiara Scirocco, Alen Zabotti(University of Udine), Michele Maria Luchetti(Ospedali Riuniti Umberto I), Bruno Laganà, Arianna D’Antonio(University of Rome Tor Vergata), Giorgio Sesti(Sapienza University of Rome), Carlo Perricone(Sapienza University of Rome), Ilaria Anna Bellofatto(University of Genoa), Simonetta Salemi(Sapienza University of Rome), G. Crepaldi(University of Turin), Caterina Baldi(University of Siena)
Cited by 1
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
Diabetes Is an Independent Predictor for Severe Osteoarthritis
|Diabetes Care|2012|334
Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): <scp>D</scp> ata from randomized controlled trials
|Diabetes Obesity and Metabolism|2017|226
Review of methods for detecting glycemic disorders
|Diabetes Research and Clinical Practice|2020|193